AOD-9604

A modified fragment of human growth hormone studied in research settings for its proposed effect on fat metabolism. Status: Research use only — not FDA-approved for weight loss or any human use.

Most of what we know about AOD-9604 comes from animal and in-vitro studies, not large, modern human outcome trials.

Preclinical data suggest AOD-9604 may:

• Increase lipolysis – stimulate breakdown of stored fat

• Reduce lipogenesis – decrease formation of new fat

• Increase fat oxidation – promote using fat as an energy source

• Possibly interact with β3-adrenergic receptors in adipose tissue, enhancing fat mobilization

Unlike full hGH, AOD-9604 does not appear to significantly raise IGF-1 or trigger classical GH-related anabolic or diabetogenic effects in preclinical models.

Reality check: these mechanisms are theoretical and model-based. Translating them into consistent, clinically meaningful weight loss in humans has been much less impressive.

1. Early Obesity Trials

AOD-9604 was tested in several Phase II trials in obese adults, primarily as oral capsules or tablets:

• Shorter Phase II studies (e.g., 12 weeks) showed:

  • Modest average weight loss, sometimes statistically greater than placebo at specific doses (around 1 mg/day in one study).

• A larger 24-week pivotal Phase IIb trial with 500+ participants found:

  • No statistically significant weight loss vs placebo at the studied doses.

  • Development as a prescription anti-obesity drug was terminated for lack of efficacy.

In other words: early hints of effect, but when tested at scale, it did not perform well enough to continue as an obesity medication.

2. Metabolic / “Nutraceutical” Studies

A later package of non-clinical work (to support use as a “nutraceutical ingredient” for metabolic health) showed:

• No evidence of genotoxicity in multiple assays

• Acceptable toxicology profile in animals at tested doses

• Rapid degradation and metabolism after oral dosing

These studies focused on safety and pharmacokinetics, not on proving large, clinically meaningful weight loss in humans.

3. Overall Efficacy Picture

Putting it together:

• Animal data: strong fat-loss and metabolic effects

• Human data:

  • Some modest weight loss and metabolic signals at specific doses

  • Inconsistent and generally underwhelming results in pivotal trials

  • Ultimately not developed as an approved obesity drug

So AOD-9604 is best described as a peptide with interesting fat-metabolism biology, but no clear, robust human efficacy as a stand-alone weight-loss medication.

• What it is: A synthetic fragment of human growth hormone (177–191) designed to modulate fat metabolism.

• Mechanism (theory): Increases lipolysis, reduces lipogenesis, and may increase fat oxidation without typical GH effects on IGF-1. Mostly shown in animal / lab models.

• Human data:

  • Some small trials show modest weight loss vs placebo at specific doses

  • A large pivotal trial found no significant advantage over placebo → obesity development program was dropped.

• Safety: Early work reports good short-term tolerability, but the FDA now flags significant concerns for compounded forms (immunogenicity, impurities, limited safety data, reports of serious adverse events).

• Regulation:

  • Not FDA-approved as a drug

  • Restricted / prohibited for compounding in the U.S.

  • Banned by WADA and anti-doping bodies at all times.

• Clinical reality: At this time, AOD-9604 should be considered an experimental peptide with limited clinical value and meaningful regulatory barriers, not a mainstream or evidence-based weight-loss therapy.

Information about AOD-9604 is provided for educational purposes only. It is not an endorsement of use. AOD-9604 is not an FDA-approved medication, and any human use should occur only within properly regulated research or under the oversight of appropriate regulatory authorities.